Challenges of SARS-CoV-2 Omicron Variant and Appropriate Countermeasures

Overview

Journal J Microbiol Immunol Infect

Specialties Allergy & Immunology
Microbiology

Date 2022 May 2

PMID 35501267

Authors

Wenxia Shao

Weiying Zhang

Xiang Fang

Daojun Yu

Xianjun Wang

Affiliations

Soon will be listed here.

Abstract

The Omicron (B.1.1.529) variant was first reported in South Africa and rapidly spread worldwide in early November 2021. This caused panic in various countries, so it is necessary to understand Omicron Variant. This paper summarizes omicron variant-related research achievements. Studies have shown that Omicron Variant contains many mutations that make it more infectious and transmissible. At the same time, immune escape is also caused, resulting in reduced efficacy of existing vaccines, increased risk of reinfection, treatment failure or reduction of monoclonal antibody therapies, and detection failure. However, current data indicate that Omicron Variant causes mild clinical symptoms and few severe cases and deaths. Omicron Variant is valid for a range of nonpharmaceutical interventions against SARS-CoV-2. Improving diagnostic accuracy and enabling timely isolation and treatment of diagnosed cases is also critical to interrupting the spread of omicron variants. COVID-19 vaccine boosters could undoubtedly help control Omicron spread and infection. However, developing a vaccine specific to Omicron Variant is also imminent.

Citing Articles

Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway.

Duran C, Riefolo F, Gini R, Barbieri E, Messina D, Garcia P Eur J Pediatr. 2024; 184(1):6.

PMID: 39535547 DOI: 10.1007/s00431-024-05864-1.

Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.

Razavi A, Raei M, Shirato K Front Immunol. 2024; 15:1462628.

PMID: 39351231 PMC: 11439707. DOI: 10.3389/fimmu.2024.1462628.

COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region.

Runge M, Karimian Z, Kheirandish M, Borghi G, Wodniak N, Fahmy K Vaccines (Basel). 2024; 12(8).

PMID: 39204033 PMC: 11360574. DOI: 10.3390/vaccines12080906.

Performance of artificial intelligence in predicting the prognossis of severe COVID-19: a systematic review and meta-analysis.

Qin C, Ma H, Hu M, Xu X, Ji C Front Public Health. 2024; 12:1371852.

PMID: 39145161 PMC: 11322443. DOI: 10.3389/fpubh.2024.1371852.

Vertical transmission of SARS-CoV-2 delta-variant in a preterm infant.

Zia M, Kumar K, Gamma E, Shakeel F, Hanna I, Lin X BMC Infect Dis. 2024; 24(1):537.

PMID: 38807052 PMC: 11134764. DOI: 10.1186/s12879-024-09420-y.

References

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

Lippi G, Adeli K, Plebani M . Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clin Chem Lab Med. 2021; 60(3):338-342. DOI: 10.1515/cclm-2021-1287. View

Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C . Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med. 2021; 386(5):492-494. PMC: 8823651. DOI: 10.1056/NEJMc2119358. View

Luo H, You C, Lu S, Fu Y . Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol. 2020; 100(1):45-52. PMC: 7572245. DOI: 10.1007/s00277-020-04305-x. View

Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q . The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2021; 11(1):1-5. PMC: 8725892. DOI: 10.1080/22221751.2021.2017757. View

Rahmani S, Rezaei N . Omicron (B.1.1.529) variant: Development, dissemination, and dominance. J Med Virol. 2021; 94(5):1787-1788. PMC: 9015373. DOI: 10.1002/jmv.27563. View

Lu L, Yee Mok B, Chen L, Chan J, Tsang O, Lam B . Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin Infect Dis. 2021; 75(1):e822-e826. PMC: 8754807. DOI: 10.1093/cid/ciab1041. View

Fabricius D, Ludwig C, Scholz J, Rode I, Tsamadou C, Jacobsen E . mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines (Basel). 2021; 9(8). PMC: 8402682. DOI: 10.3390/vaccines9080918. View

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View

10.

Hoffmann M, Kruger N, Schulz S, Cossmann A, Rocha C, Kempf A . The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022; 185(3):447-456.e11. PMC: 8702401. DOI: 10.1016/j.cell.2021.12.032. View

11.

Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

12.

Pascarella S, Ciccozzi M, Bianchi M, Benvenuto D, Cauda R, Cassone A . The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta-plus variants: A hint to higher transmissibility?. J Med Virol. 2021; 94(4):1277-1280. DOI: 10.1002/jmv.27528. View

13.

Tian D, Sun Y, Zhou J, Ye Q . The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. Front Immunol. 2021; 12:751778. PMC: 8669155. DOI: 10.3389/fimmu.2021.751778. View

14.

Kumar S, Thambiraja T, Karuppanan K, Subramaniam G . Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2021; 94(4):1641-1649. DOI: 10.1002/jmv.27526. View

15.

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

16.

Bekliz M, Adea K, Essaidi-Laziosi M, Sacks J, Escadafal C, Kaiser L . SARS-CoV-2 antigen-detecting rapid tests for the delta variant. Lancet Microbe. 2021; 3(2):e90. PMC: 8612709. DOI: 10.1016/S2666-5247(21)00302-5. View

17.

Brandal L, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U . Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021; 26(50). PMC: 8728491. DOI: 10.2807/1560-7917.ES.2021.26.50.2101147. View

18.

Dyer O . Covid-19: South Africa's surge in cases deepens alarm over omicron variant. BMJ. 2021; 375:n3013. DOI: 10.1136/bmj.n3013. View

19.

Han X, Xu P, Ye Q . Analysis of COVID-19 vaccines: Types, thoughts, and application. J Clin Lab Anal. 2021; 35(9):e23937. PMC: 8418485. DOI: 10.1002/jcla.23937. View

20.

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View